Akt Inhibitor MK2206

Malignant Breast Neoplasm

→ investigated for

Malignant Breast Neoplasmcancer_family

2 source records aggregated

supports

Curated

Malignant Colorectal Neoplasm

→ investigated for

Malignant Colorectal Neoplasmsubtype

supports

Curated

→ investigated for

Cutaneous Melanomacancer

supports

Cutaneous Melanoma

Curated

Ovarian Serous Cystadenocarcinoma

→ investigated for

Ovarian Serous Cystadenocarcinomasubtype

supports

Curated

Malignant Breast Neoplasm

Akt Inhibitor MK2206 investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 143show all (up to 200)
→ investigated in trials for	Malignant Breast Neoplasmcancer_family 9 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Breast Neoplasm	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Breast Carcinoma 5 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Breast Carcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Neoplasm 4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Chronic Lymphocytic Leukemia 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Chronic Lymphocytic Leukemia	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Non-Small Cell Carcinoma 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Small Lymphocytic Lymphoma 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Small Lymphocytic Lymphoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Solid Neoplasm 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Hepatocellular Carcinoma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Hepatocellular Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Liver Carcinoma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Liver Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Solid Neoplasm 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Solid Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Diffuse Large B-Cell Lymphoma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Diffuse Large B-Cell Lymphoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Gastroesophageal Junction Adenocarcinoma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Gastroesophageal Junction Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Grade 1 Follicular Lymphoma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Grade 1 Follicular Lymphoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Grade 2 Follicular Lymphoma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Grade 2 Follicular Lymphoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Grade 3 Follicular Lymphoma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Grade 3 Follicular Lymphoma	2	Observed	clinicaltrials	graph →

Akt Inhibitor MK2206 investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 143show all (up to 200)

→ investigated in trials for

Malignant Breast Neoplasmcancer_family

9 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

→ investigated in trials for

Breast Carcinoma

5 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Breast Carcinoma

Observed

→ investigated in trials for

Malignant Neoplasm

4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Neoplasm

Observed

Chronic Lymphocytic Leukemia

→ investigated in trials for

3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Chronic Lymphocytic Leukemia

Observed

Lung Non-Small Cell Carcinoma

→ investigated in trials for

3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Lung Non-Small Cell Carcinoma

Observed

Small Lymphocytic Lymphoma

→ investigated in trials for

3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Small Lymphocytic Lymphoma

Observed

→ investigated in trials for

Solid Neoplasm

3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Solid Neoplasm

Observed

Adult Hepatocellular Carcinoma

→ investigated in trials for

2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Adult Hepatocellular Carcinoma

Observed

→ investigated in trials for

Adult Liver Carcinoma

2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Adult Liver Carcinoma

Observed

→ investigated in trials for

Adult Solid Neoplasm

2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Adult Solid Neoplasm

Observed

Diffuse Large B-Cell Lymphoma

→ investigated in trials for

2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Diffuse Large B-Cell Lymphoma

Observed

Gastroesophageal Junction Adenocarcinoma

→ investigated in trials for

2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Gastroesophageal Junction Adenocarcinoma

Observed

Grade 1 Follicular Lymphoma

→ investigated in trials for

2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Grade 1 Follicular Lymphoma

Observed

Grade 2 Follicular Lymphoma

→ investigated in trials for

2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Grade 2 Follicular Lymphoma

Observed

Grade 3 Follicular Lymphoma

→ investigated in trials for

2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Grade 3 Follicular Lymphoma

Observed

Malignant Solid Neoplasm,Cutaneous Melanoma,Malignant Prostate Neoplasm+1

Akt Inhibitor MK2206 studied in …STUDIED_INderived10 of 45show all (up to 200)
→ studied in	NCT01480154Phase 1 · active not recruiting Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer · 45 trials list this drug (1 active)	—	—	Malignant Solid Neoplasm,Cutaneous Melanoma,Malignant Prostate Neoplasm+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT01251861Phase 2 · completed Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer · 45 trials list this drug (1 active)	—	—	Malignant Prostate Neoplasm,Prostate Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01306045Phase 2 · completed Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies · 45 trials list this drug (1 active)	—	—	Thymus Carcinoma,Lung Non-Small Cell Carcinoma,Lung Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00963547Phase 1 · terminated A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015) · 45 trials list this drug (1 active)	—	—	Solid Neoplasm,Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT01307631Phase 2 · completed Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer · 45 trials list this drug (1 active)	—	—	Endometrial Adenocarcinoma,Endometrial Serous Adenocarcinoma,Endometrial Adenosquamous Carcinoma+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT01248247Phase 2 · completed BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer · 45 trials list this drug (1 active)	—	—	Malignant Lung Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT01258998Phase 2 · completed Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma · 45 trials list this drug (1 active)	—	—	Anaplastic Large Cell Lymphoma,Hairy Cell Leukemia,Non-Hodgkin Lymphoma+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT00848718Phase 1 · completed A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003) · 45 trials list this drug (1 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT01239342Phase 2 · terminated Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer · 45 trials list this drug (1 active)	—	—	Kidney Carcinoma,Renal Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01802320Phase 2 · completed Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery · 45 trials list this drug (1 active)	—	—	Colon Carcinoma,Colon Mucinous Adenocarcinoma,Colon Signet Ring Cell Adenocarcinoma+2	1	Observed	clinicaltrials	graph →

Akt Inhibitor MK2206 studied in …STUDIED_INderived10 of 45show all (up to 200)

→ studied in

NCT01480154Phase 1 · active not recruiting

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer · 45 trials list this drug (1 active)

—

Observed

Malignant Prostate Neoplasm,Prostate Carcinoma

→ studied in

NCT01251861Phase 2 · completed

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer · 45 trials list this drug (1 active)

—

Observed

Thymus Carcinoma,Lung Non-Small Cell Carcinoma,Lung Small Cell Carcinoma

→ studied in

NCT01306045Phase 2 · completed

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies · 45 trials list this drug (1 active)

—

Observed

Solid Neoplasm,Malignant Breast Neoplasm

→ studied in

NCT00963547Phase 1 · terminated

A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015) · 45 trials list this drug (1 active)

—

Observed

Endometrial Adenocarcinoma,Endometrial Serous Adenocarcinoma,Endometrial Adenosquamous Carcinoma+1

→ studied in

NCT01307631Phase 2 · completed

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer · 45 trials list this drug (1 active)

—

Observed

→ studied in

NCT01248247Phase 2 · completed

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer · 45 trials list this drug (1 active)

—

Malignant Lung Neoplasm

Observed

Anaplastic Large Cell Lymphoma,Hairy Cell Leukemia,Non-Hodgkin Lymphoma+2

→ studied in

NCT01258998Phase 2 · completed

Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma · 45 trials list this drug (1 active)

—

Observed

→ studied in

NCT00848718Phase 1 · completed

A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003) · 45 trials list this drug (1 active)

—

not mapped

Observed

Kidney Carcinoma,Renal Cell Carcinoma

→ studied in

NCT01239342Phase 2 · terminated

Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer · 45 trials list this drug (1 active)

—

Observed

Colon Carcinoma,Colon Mucinous Adenocarcinoma,Colon Signet Ring Cell Adenocarcinoma+2

→ studied in

NCT01802320Phase 2 · completed

Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery · 45 trials list this drug (1 active)

—

Observed